Carboplatin Plus Vincristine in Treating Children With Retinoblastoma
NCT00002794
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin plus vincristine in treating children with retinoblastoma.
Gender:
ALL
Ages:
10 years and below
Trial Updated:
10/03/2011
Locations: University of Tennessee, Memphis Cancer Center, Memphis, Tennessee +1 locations
Conditions: Retinoblastoma
Register for Updates
Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors
NCT00541138
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Tamoxifen may help carboplatin work better by making tumor cells more sensitive to the drug. PURPOSE: This phase II trial is studying the side effects of giving carboplatin and topotecan together with tamoxifen and to see how well it works in treating patients with central nervous system metastases or r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/20/2011
Locations: City of Hope Comprehensive Cancer Center, Duarte, California
Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy
NCT00505492
Terminated
Primary Objectives: 1. To test whether the addition of chemotherapy to radiotherapy improves the progression-free survival for patients with stage I, II and IIIa malignant mixed mesodermal tumor (MMMT) of the uterus. 2. To determine the acute and late toxicity profiles associated with this treatment regimen. 3. To describe the effect of this treatment regimen on the patient's quality of life.
Gender:
FEMALE
Ages:
All
Trial Updated:
09/13/2011
Locations: UT MD Anderson Cancer Center, Houston, Texas +1 locations
Conditions: Uterine Neoplasms
Register for Updates
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
NCT00003690
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of flavopiridol plus cisplatin or carboplatin in treating patients who have advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2011
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Breast Cancer, Melanoma (Skin), Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia
NCT00002693
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy with carboplatin and topotecan in treating patients with chronic myelogenous leukemia or recurrent acute leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2011
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Leukemia, Neutropenia
Register for Updates
Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma
NCT00145639
Completed
This trial (OS99) evaluates the use of ifosfamide, carboplatin, and doxorubicin in an up-front window before surgery for localized and resectable osteosarcoma. High-dose methotrexate, which may interfere with the dose-intensive delivery of other agents, is eliminated from the treatment of localized disease. The primary objective is to compare the response rate of pre-surgical chemotherapy comprised of ifosfamide, doxorubicin, and carboplatin to that obtained with ifosfamide and carboplatin in th... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
06/08/2011
Locations: Arkansas Children's Hospital, Little Rock, Arkansas +3 locations
Conditions: Osteosarcoma
Register for Updates
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
NCT00343291
Completed
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2011
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Decatur, Alabama +42 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors
NCT00193583
Completed
In this phase I study we will characterize the safety, tolerability, maximum tolerated dose and dose-limiting toxicity of weekly bolus topotecan when administered in combination with two different dosing schedules of carboplatin. We will also evaluate any antitumor activity of these combination regimens.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2011
Locations: Tennessee Oncology, PLLC, Nashville, Tennessee
Conditions: Cancer
Register for Updates
Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer
NCT00193076
Completed
Pre-clinical data suggests that combination therapy with gemcitabine and carboplatin is synergistic, and both drugs may be synergistic with trastuzumab. Additionally, recent clinical data suggest that the combination of gemcitabine with platinum is an active regimen in metastatic breast cancer. This study will test the combination of gemcitabine with carboplatin in patients with metastatic breast cancer. Patients with Her2/neu overexpression will be stratified to receive trastuzumab in addition... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/02/2011
Locations: Tennessee Oncology, Nashville, Tennessee
Conditions: Breast Cancer
Register for Updates
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
NCT00193505
Completed
In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2011
Locations: Tennessee Oncology, PLLC, Nashville, Tennessee
Conditions: Non-Hodgkins Lymphoma
Register for Updates
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00028912
Completed
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy such as carboplatin use different ways to stop tumor cells from dividing so they stop growing or die. Bortezomib may help carboplatin kill more tumor cells by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining bortezomib with carboplatin in treating patients who have recurrent or progressive ovaria... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
04/23/2011
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
NCT00528619
Completed
This study will assess the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/07/2011
Locations: Pfizer Investigational Site, Aurora, Colorado +2 locations
Conditions: Neoplasms
Register for Updates